TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03823846
Drug: Adjusted Dynastat or Flurbiprofen Axetil jinjection
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
Study: NCT03823846
Drug: normal analgesia pump administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of analgesia pump was added if needed.
Study: NCT03823846
Drug: adjusted analgesia pump administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
Study: NCT03899064
Drug: Induction: Application of MC2-01 Cream, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03899064
Drug: Induction: Application of MC2-01 Cream, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03899064
Drug: Induction: Applications of MC2-01 vehicle, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03899064
Drug: Induction: Applications of MC2-01 vehicle, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03899064
Drug: Challenge: Application of MC2-01 Cream, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT03899064
Drug: Challenge: Application of MC2-01 Cream, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT03899064
Drug: Challenge: Applications of MC2-01 vehicle, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT03899064
Drug: Challenge: Applications of MC2-01 vehicle, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT03899064
Drug: Challenge: Control, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Study: NCT00650455
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 10 mg tablet once daily for 12 weeks
Study: NCT00650455
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg capsule twice daily for 12 weeks
Study: NCT00650455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet every morning and capsule every evening for 12 weeks
Study: NCT03952715
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
Study: NCT03952715
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
Study: NCT01454349
Drug: PRX302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
Study: NCT01454349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection of matching placebo
Study: NCT00628589
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo
Study: NCT02253823
Drug: TPV/RTV - low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253823
Drug: TPV/RTV - high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02418312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus thienopyridine
Study: NCT02303782
Drug: OTX015
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03542916
Drug: CJ-40001 60ug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-40001 60ug SC, IV injection
Study: NCT03542916
Drug: NESP 60ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP 60ug SC, IV injection
Study: NCT01307202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match the the gabapentin pill and will be given orally.
Study: NCT03483870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of normal saline 0.9% IV injection
Study: NCT00289198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray
Study: NCT01960088
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01414764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively
Study: NCT03421743
Drug: Antimycobacterial regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug NTM guideline-based antimycobacterial regimen
Study: NCT00431951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules to match experimental drug
Study: NCT01293643
Drug: 100 mg clindamycin /800 mg ketoconazole vaginal ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal ovule for 3 consecutive days
Study: NCT01293643
Drug: 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 applicator (4 g) full of cream intravaginally for 7 to 10 days
Study: NCT01296074
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Study: NCT03900923
Drug: 98% pure CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
Study: NCT01939132
Drug: Open label H.P. Acthar Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
Study: NCT01009346
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001
Study: NCT00424411
Drug: Inhaled human insulin (EXUBERA™)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01532544
Drug: low molecular weight heparin.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00174538
Drug: Codeine (30 mg)
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00693472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule administered orally every 12 hours
Study: NCT00693472
Drug: Anticholinergic agents or propanolol
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.
Study: NCT02768714
Drug: Neulastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
Study: NCT01790555
Drug: Namisol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00690170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
Study: NCT04375397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Study: NCT01304329
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium dose oral administration
Study: NCT02973191
Drug: JCAR015
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01797380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for duration of double-blind portion of trial
Study: NCT03508323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T/qd
Study: NCT05052437
Drug: Utidelone Injection; capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
Study: NCT03561701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT03542435
Drug: SXC-2023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03542435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05551624
Drug: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
Study: NCT02784015
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784015
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00624780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01152515
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
Study: NCT01169584
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
Study: NCT01825902
Drug: fluorine F 18 fluorothymidine
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo 18F-FLT PET
Study: NCT03476616
Drug: Eplerenone (-based therapy) arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
Study: NCT04407065
Drug: Double trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Study: NCT04407065
Drug: HCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study: NCT04015869
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02474537
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200 mg dose INC280
Study: NCT01812369
Drug: METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02501564
Drug: Naproxen Sodium Codeine
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet twice a day
Study: NCT02501564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice a day
Study: NCT00837876
Drug: Erlotinb
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg taken by mouth 1 time per day.
Study: NCT03077555
Drug: Meliane ED
Approvals — FDA: no, EMA: no, PMDA: no
Description: quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
Study: NCT03558074
Drug: ALK4290
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK4290 400 mg tablet twice a day
Study: NCT01116427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
Study: NCT00461305
Drug: DRSP 3 mg/EE 20 µg (13 cycles)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
Study: NCT00461305
Drug: DRSP 3 mg/EE 30 µg (6 cycles)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Study: NCT03609619
Drug: AEVI-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
Study: NCT03609619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of Placebo will be administered twice daily, during the treatment period.
Study: NCT04900948
Drug: cream 0.1% methylprednisolone aceponate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
Study: NCT00657384
Drug: Nacl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
Study: NCT02177409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02639338
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study: NCT02639338
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study: NCT02911688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
Study: NCT00809328
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
Study: NCT01634529
Drug: V158866
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending oral doses of V158866 and Placebo
Study: NCT01634529
Drug: V158866
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending oral doses of V158866 and Placebo
Study: NCT03825692
Drug: Zhizhu Kuanzhong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Study: NCT03825692
Drug: Zhizhu Kuanzhong Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Study: NCT00849602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid for three days
Study: NCT01172756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT02482857
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare BID dosing with OD dosing with clinically used aspirin dosages.
Study: NCT02310048
Drug: MT-1303-FormA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02630368
Drug: Cyclophosphamide and JX-594 dose escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Study: NCT02630368
Drug: Cyclophosphamide and JX-594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Study: NCT02630368
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
Study: NCT02630368
Drug: Avelumab and JX-594 and Cyclophosphamide
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Study: NCT04493684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally during each dosing day.
Study: NCT04493684
Drug: GSK3739937 (Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3739937 Tablet will be administered via oral route.
Study: NCT03449433
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03781791
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in tablet form, once daily.
Study: NCT02449018
Drug: QBW251
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBW251 capsule(s) taken orally twice per day
Study: NCT02449018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule(s) taken orally twice per day
Study: NCT00806442
Drug: Borage Seed Oil and Echium Seed Oil
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
Study: NCT04412694
Drug: Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative oral dexamathasone supplementation in a single dose of 8mg.
Study: NCT04412694
Drug: Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative oral supplementation of sweetener in a single dose.
Study: NCT00744666
Drug: Prednisolone 1% topical eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1% 1gtt qid to the eye requiring IVTA
Study: NCT00180167
Drug: randomization between two established Chemotherapies
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02103374
Drug: Atrovent + Bricanyl or Atrovent + Ventoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
Study: NCT02103374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule lactose during 48 weeks